Phase I study of mTORC1/2 inhibitor sapanisertib in combination with metformin in patients with mTOR/AKT/PI3K pathway alterations and advanced solid malignancies

CONCLUSIONS: The safety profile of mTORC1/2 inhibitor sapanisertib in combination with metformin was generally tolerable, with anti-tumor activity observed in patients with advanced malignancies harboring PTEN/ AKT/mTOR pathway alterations.PMID:38126764 | DOI:10.1158/2767-9764.CRC-22-0260

Source: Cancer Control - December 21, 2023 Category: Cancer & Oncology Authors: Vivek Subbiah Niamh Coleman Sarina A Piha-Paul Apostolia M Tsimberidou Filip Janku Jordi Rodon Shubham Pant Ecaterina E Dumbrava Siqing Fu David S Hong Shizhen Zhang Ming Sun Yunfang Jiang Jason Roszik Juhee Song Ying Yuan Funda Meric-Bernstam Aung Naing Source Type: research